<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009211067
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Enzastik 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENZALUTAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, soft
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        112
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8979.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Eugia Pharma Specialties Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Eugia Pharma Specialties Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is Enzastik ?</strong></p><p>Enzastik contains the active substance enzalutamide. Enzastik is used to treat adult men with prostate cancer that no longer responds to androgen deprivation therapy.</p><p><strong>How Enzastik works</strong></p><p>Enzastik is a medicine that works by blocking the activity of hormones called androgens (such as testosterone). By blocking androgens, enzalutamide stops prostate cancer cells from growing and dividing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Enzastik :</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to enzalutamide or any of the other ingredients of this medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or may become pregnant (see &lsquo;Pregnancy, breast-feeding and fertility&rsquo;)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><u>Seizures</u></p><p>Seizures were reported in 4 in every 1,000 people taking Enzastik , and fewer than one in every 1,000 people taking placebo (see &lsquo;Other medicines and Enzastik &rsquo; below and section 4 &lsquo;Possible side effects&rsquo;).</p><p>If you are taking a medicine that can cause seizures or that can increase the susceptibility for having seizures (see &lsquo;Other medicines and Enzastik &rsquo; below)</p><p>If you have a seizure during treatment:</p><p>See your doctor as soon as possible. Your doctor may decide that you should stop taking Enzastik</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>There have been rare reports of PRES, a rare, reversible condition involving the brain, in patients treated with Enzastik . If you have a seizure, worsening headache, confusion, blindness or other vision problems, please contact your doctor as soon as possible. (See also section 4 &lsquo;Possible side effects&rsquo;).</p><p>Talk to your doctor before taking Enzastik</p><p>- If you are taking any medicines to prevent blood clots (e.g. warfarin, acenocoumarol, clopidogrel)</p><p>- If you use chemotherapy like docetaxel</p><p>- If you have problems with your liver</p><p>- If you have problems with your kidneys</p><p>&nbsp;</p><p>Please tell your doctor if you have any of the following:</p><p>Any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions. The risk of heart rhythm problems may be increased when using Enzastik</p><p>If you are allergic to enzalutamide, this may result in a rash or swelling of the face, tongue, lip or throat. If you are allergic to enzalutamide or any of the other ingredients of this medicine, do not take Enzastik .</p><p>&nbsp;</p><p><strong>If any of the above applies to you or you are not sure, talk to your doctor before taking this medicine.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>This medicine is not for use in children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and Enzastik </strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. You need to know the names of the medicines you take. Keep a list of them with you to show to your doctor when you are prescribed a new medicine. You should not start or stop taking any medicine before you talk with the doctor that prescribed Enzastik .</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines. When taken at the same time as Enzastik , these medicines may increase the risk of a seizure:</p><p>- Certain medicines used to treat asthma and other respiratory diseases (e.g. aminophylline, theophylline).</p><p>- Medicines used to treat certain psychiatric disorders such as depression and schizophrenia (e.g. clozapine, olanzapine, risperidone, ziprasidone, bupropion, lithium, chlorpromazine, mesoridazine, thioridazine, amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine).</p><p>- Certain medicines for the treatment of pain (e.g. pethidine).</p><p>&nbsp;</p><p>Tell your doctor if you are taking the following medicines. These medicines may influence the effect of ENZASTIK, or ENZASTIK may influence the effect of these medicines.</p><p>This includes certain medicines used to:</p><p>- Lower cholesterol (e.g. gemfibrozil, atorvastatin, simvastatin)</p><p>- Treat pain (e.g. fentanyl, tramadol)</p><p>- Treat cancer (e.g. cabazitaxel)</p><p>- Treat epilepsy (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)</p><p>- Treat certain psychiatric disorders such as severe anxiety or schizophrenia (e.g. diazepam, midazolam, haloperidol)</p><p>- Treat sleep disorders (e.g. zolpidem)</p><p>- Treat heart conditions or lower blood pressure (e.g. bisoprolol, digoxin, diltiazem, felodipine,</p><p>nicardipine, nifedipine, propranolol, verapamil)</p><p>- Treat serious disease related to inflammation (e.g. dexamethasone, prednisolone)</p><p>- Treat HIV infection (e.g. indinavir, ritonavir)</p><p>- Treat bacterial infections (e.g. clarithromycin, doxycycline)</p><p>- Treat thyroid disorders (e.g. levothyroxine)</p><p>- Treat gout (e.g. colchicine)</p><p>- Treat stomach disorders (e.g. omeprazole)</p><p>- Prevent heart conditions or strokes (e.g. dabigatran etexilate)</p><p>- Prevent organ rejection (e.g. tacrolimus)</p><p>&nbsp;</p><p>Enzastik might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used with some other medicines (e.g. methadone, used for pain relief and part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics used for serious mental illnesses).</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the medicines listed above. The dose of ENZASTIK or any other medicines that you are taking may need to be changed.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>- Enzastik is not for use in women. This medicine may cause harm to the unborn child or potential loss of pregnancy if taken by women who are pregnant. It must not be taken by women who are pregnant, may become pregnant, or who are breast-feeding.</p><p>- This medicine could possibly have an effect on male fertility.</p><p>- If you are having sex with a woman who can become pregnant, use a condom and another effective birth control method, during treatment and for 3 months after treatment with this medicine. If you are having sex with a pregnant woman, use a condom to protect the unborn child.</p><p>- Female caregivers see section 3 &lsquo;How to take ENZASTIK&rsquo; for handling and use.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This medicine has moderate effect on your ability to drive or use any tools or machines as the side effects of ENZASTIK include psychiatric and neurological events including seizure. If you are at higher risk of seizures, talk to your doctor.</p><p>&nbsp;</p><p><strong>Enzastik </strong><strong>contains sorbitol</strong></p><p>This medicine contains 57.8 mg sorbitol (a type of sugar) per soft capsule. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The usual dose is 160 mg (four soft capsules), taken at the same time once a day.</p><p><strong>Taking Enzastik&nbsp;</strong></p><p>- Swallow the soft capsules whole with water.</p><p>- Do not chew, dissolve or open the soft capsules before swallowing.</p><p>- Enzastik&nbsp;can be taken with or without food.</p><p>- Enzastik&nbsp;should not be handled by persons other than the patient and his caregivers, and especially not by women who are or may become pregnant.</p><p>Your doctor may also prescribe other medicines while you are taking Enzastik&nbsp;.</p><p><strong>If you take more Enzastik&nbsp;than you should</strong></p><p>If you take more soft capsules than prescribed, stop taking Enzastik&nbsp;and contact your doctor. You may have an increased risk of seizure or other side effects.</p><p><strong>If you forget to take Enzastik&nbsp;</strong></p><p>- If you forget to take Enzastik&nbsp;at the usual time, take your usual dose as soon as you remember.</p><p>- If you forget to take Enzastik&nbsp;for the whole day, take your usual dose the following day.</p><p>- If you forget to take Enzastik&nbsp;for more than one day, talk to your doctor immediately.</p><p>- <strong>Do not take a double dose to make up for the dose you forgot.</strong></p><p><strong>If you stop taking Enzastik&nbsp;</strong></p><p>Do not stop taking this medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Seizures</strong></p><p>Seizures were reported in 4 in every 1,000 people taking Enzastik , and in fewer than one in every 1,000 people taking placebo.</p><p>Seizures are more likely if you take more than the recommended dose of this medicine, if you take certain other medicines, or if you are at higher than usual risk of seizure.</p><p><strong>If you have a seizure</strong>, see your doctor as soon as possible. Your doctor may decide that you should stop taking Enzastik .</p><p>&nbsp;</p><p><strong>Posterior Reversible Encephalopathy Syndrome (PRES)</strong></p><p>There have been rare reports of PRES (may affect up to 1 in 1,000 people), a rare, reversible condition involving the brain, in patients treated with Enzastik . If you have a seizure, worsening headache, confusion, blindness or other vision problems, please contact your doctor as soon as possible.</p><p>Other possible side effects include:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>Tiredness, broken bones, hot flushes, high blood pressure</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>Headache, fall, feeling anxious, dry skin, itching, difficulty remembering, blockage of the arteries in the heart (ischemic heart disease), breast enlargement in men (gynaecomastia), symptom of restless legs syndrome (an uncontrollable urge to move a part of the body, usually the leg), reduced concentration, forgetfulness</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>Hallucinations, difficulty thinking clearly, low white blood cell count</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>Muscle pain, muscle spasms, muscular weakness, back pain, changes in ECG (QT prolongation), upset stomach including feeling sick (nausea), rash, being sick (vomiting), swelling of the face, lips, tongue and/or throat, reduction in blood platelets (which increases risk of bleeding or bruising), diarrhea</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C.</p><p>Do not take any soft capsule that is leaking, damaged, or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Enzalutamide.</p><p>Each capsule contains Enzalutamide 40 mg.</p><p>The other ingredients are:</p><p><em>The other ingredients </em>are<em> </em>Caprylocaproyl Polyoxyglycerides, Butylhydroxyanisole and Butylhydroxytoluene</p><p><em>The ingredients of the soft capsule shell </em>are Gelatin, Sorbitol Sorbitan Solution, Glycerin and Titanium dioxide.</p><p><em>The ingredients of the ink</em> are Black Iron oxide and Hypromellose)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Enzastik 40: 
White to off-white, oblong shape soft gelatin capsule imprinted in black ink with “E40”, containing pale yellow to yellow color solution.
Each carton contains 112 soft capsules in 4 blister wallets of 28 soft capsules each.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer </strong></p><p>Eugia Pharma Specialities Limited,</p><p>Survey No. 550, 551 &amp; 552, Kolthur Village,</p><p>Shamirpet Mandal, Medchal-Malkajgiri District,</p><p>Telangana, India.</p><p><strong>Marketing Authorisation Holder </strong></p><p>Aurobindo Pharma Limited</p><p>Plot.No:2, Maithrivihar, Ameerpet,</p><p>Hyderabad, Telangana, INDIA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;ما هو إنزاستيك؟</strong></p><p dir="RTL">يحتوي إنزاستيك على المادة الفعالة إينزالوتاميد، ويُستخدم إنزاستيك لعلاج الرجال البالغين المصابين بسرطان البروستاتا، والذين لم يعودوا يستجيبون لعلاج منع الأندروجين.</p><p dir="RTL"><strong>كيف يعمل إنزاستيك</strong></p><p dir="RTL">إنزاستيك هو دواء يعمل عبر كبح نشاط هرمونات تُسمى الأندروجينات (مثل التستوستيرون). وعبر كبح الأندروجينات، يمنع إينزالوتاميد خلايا سرطان البروستاتا من النمو والانقسام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ إنزاستيك:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مصابًا بالحساسية ضد إينزالوتاميد أو أي مكون آخر من مكونات هذا الدواء.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنتِ حاملًا (انظر القسم &quot;الحمل والرضاعة الطبيعية والخصوبة&rsquo;)</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><u>النوبات</u></p><p dir="RTL">أُبلغ عن حدوث نوبات مع 4 لكل 1000 شخص يأخذ إنزاستيك، وأقل من واحد لكل 1000 شخص يأخذ الدواء الوهمي (انظر &quot;الأدوية الأخرى وإنزاستيك&quot; أدناه والقسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">إن كنت تأخذ أدوية من شأنها التسبب في نوبات أو زيادة الميل لحدوث نوبات (انظر &quot;الأدوية الأخرى وإنزاستيك&quot; أدناه)،</p><p dir="RTL">أو إن أُصبت بنوبة أثناء العلاج،</p><p dir="RTL">تحدث مع طبيبك في أقرب وقت ممكن، فقد يقرر الطبيب ضرورة إيقاف إنزاستيك.</p><p>&nbsp;</p><p dir="RTL"><u>متلازمة اعتلال الدماغ الخلفي العكسية (</u><u>PRES</u><u>) </u></p><p dir="RTL">هناك تقارير نادرة عن حدوث متلازمة اعتلال الدماغ الخلفي العكسية (PRES)، وهي حالة نادرة قابلة للشفاء تُصيب الدماغ، لدي المرضى الذين عولجوا بإنزاستيك. إن أُصبت بنوبة أو تفاقم بالصداع أو ارتباك أو عمى أو أي مشاكل بصرية أخرى، من فضلك تواصل مع طبيبك على الفور. (انظر أيضًا القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">تحدث مع طبيبك قبل أخذ إنزاستيك</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنت تأخذ أي أدوية تمنع تجلط الدم (مثل وارفارين، أسينوكومارول، كلوبيدوجريل)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنت تستخدم علاج كيميائي مثل دوسيتاكسيل</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنت مصابًا بمشاكل في الكبد</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنت مصابًا بمشاكل في الكلى</p><p dir="RTL">يُرجى أن تُعلم طبيبك إن كان لديك أي من التالي:</p><p dir="RTL">أي حالة بالقلب أو الأوعية الدموية، بما في ذلك مشاكل نظم القلب (اضطراب النظم)، أو إن كنت تُعالج بأدوية مخصصة لتلك الحالات، فقد تزداد خطورة الإصابة بمشاكل اضطراب النظم عند استخدام إنزاستيك.</p><p>إن كانت لديك حساسية تجاه إينزالوتاميد، قد ينتج عن ذلك طفح أو تورم بالوجه أو اللسان أو الشفتين أو الحلق. لا تأخذ إنزاستيك إذا كنت مصابًا بالحساسية تجاه إينزالوتاميد أو أي مكون آخر من مكونات هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>إن انطبق أي مما سبق عليك أو إن لم تكن متأكدًا، تحدث مع الطبيب قبل أخذ هذا الدواء.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">هذا الدواء غير مخصص لاستعمال الأطفال والمراهقين.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وإنزاستيك</strong></p><p dir="RTL">أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي دواء آخر. أنت في حاجة لمعرفة أسماء الأدوية التي تأخذها، لذا احتفظ بقائمة بهم كي تعرضها على طبيبك عندما يصف لك دواءً جديدًا. يجب ألا تبدأ أي دواء أو توقفه قبل التحدث مع الطبيب الذي وصف إنزاستيك.</p><p dir="RTL">أعلم طبيبك إن كنت تستخدم أي من الأدوية التالية، فقد تُزيد تلك الأدوية من خطر الإصابة بالنوبات عند أخذها<strong> </strong>مع إنزاستيك:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعض الأدوية التي تُستخدم لعلاج الربو والأمراض التنفسية الأخرى (مثل أمينوفيللين، ثيوفيللين).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الأدوية التي تُستخدم لعلاج بعض الاضطرابات النفسية مثل الاكتئاب والفصام (مثل كلوزابين، أولانزابين، ريسبيريدون، زيبراسيدون، بوبروبيون، الليثيوم، كلوربرومازين، ميزوريدازين، ثيوريدازين، أميتريبتايلين، ديسيبرامين، دوكسيبين، إيميبرامين، مابروتيلين، ميرتازابين).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعض أدوية علاج الألم (مثل بيثيدين).</p><p dir="RTL">أعلم طبيبك إذا كنت تأخذ أي من الأدوية التالية، فقد تؤثر تلك الأدوية على آلية إنزاستيك، أو قد يؤثر إنزاستيك على آلية تلك الأدوية.</p><p dir="RTL">ذلك يتضمن بعد الأدوية المستخدمة في:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>خفض الكوليستيرول (مثل جيمفيبروزيل، أتورفاستاتين، سيمفاستاتين)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج الآلام (مثل فينتانيل، ترامادول)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج السرطان (مثل كابازيتاكسيل)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج الصرع (مثل كاربامازيبين، كلونازيبام، فينايتوين، بريميدون، حامض الفالبرويك)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج بعض الاضطرابات النفسية مثل القلق الشديد أو الفصام (مثل ديازيبام، ميدازولام، هالوبيريدول)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج اضطرابات النوم (مثل زولبيديم)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج حالات القلب أو انخفاض ضغط الدم (مثل بيسوبرولول، ديجوكسين، ديلتيازيم، فيلوديبين،<strong> </strong>نيكارديبين، نيفيديبين، بروبرانولول، فيراباميل)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج الأمراض الخطيرة المتعلقة بالالتهاب (مثل ديكساميثازون، بريدنيسولون)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج عدوى فيروس نقص المناعة البشرية (HIV) (مثل إندينافير، ريتونافير)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج العدوات البكتيرية (مثل كلاريثرومايسين، دوكسيسيكلين)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج اضطراب الغدة الدرقية (مثل ليفوثيروكسين)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج القلاع (مثل كولشيسين)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>علاج اضطرابات المعدة (مثل أوميبرازول)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>منع حالات القلب أو السكتات الدماغية (مثل دابيجاتران إيتاكسيلات)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>منع رفض الأعضاء (مثل تاكروليموس)</p><p>&nbsp;</p><p dir="RTL">قد يتداخل إنزاستيك مع بعض الأدوية المستخدمة لعلاج مشاكل نظم القلب (مثل كينيدين، بروكيناميد، أميودارون، سوتالول)، أو قد تُزيد من خطر مشاكل نظم القلب عند استخدامه مع بعض الأدوية الأخرى (مثل ميثادون، المستخدم كمسكن للألم وكجزء من إزالة التسمم الناتج عن إدمان العقاقير، موكسيفلوكساسين (مضاد حيوي)، مضادات الذهان المستخدمة للأمراض العقلية الشديدة).</p><p dir="RTL">أعلم طبيبك إن كنت تستخدم أي من الأدوية المذكورة أعلاه، فقد تكون هناك حاجة لتغيير جرعة إنزاستيك أو أي دواء آخر تأخذه.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إنزاستيك غير مخصص للاستخدام من قبل النساء. قد يتسبب هذا الدواء في إضرار الجنين أو احتمالية فقدان الحمل إن أخذته النساء الحوامل. يجب ألا تأخذه النساء الحوامل أو المحتمل حملهن أو الذين يقمن بالإرضاع الطبيعي.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قد يؤثر هذا الدواء على خصوبة الرجال.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>في حالة ممارسة الجنس مع امرأة يُحتمل حملها، استخدم واقِ ذكري ووسيلة منع حمل فعالة أخرى، وذلك أثناء العلاج ولمدة 3 شهور بعد العلاج بهذا الدواء. في حالة ممارسة الجنس مع امرأة حامل، استخدم واقِ ذكري لحماية الجنين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>على مقدمات الرعاية النسائية النظر في القسم 3 &quot;كيفية أخذ إنزاستيك&quot; للتعامل والاستعمال.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لهذا الدواء تأثير متوسط على قدرتك على القيادة أو استخدام أي أدوات أو آلات، حيث أن الآثار الجانبية لإنزاستيك تتضمن أحداث نفسية وعصبية بما في ذلك النوبات. تحدث مع طبيبك إذا كنت عرضة للإصابة بالنوبات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي على إنزاستيك على السوربيتول</strong></p><p dir="RTL">يحتوي إنزاستيك على 57.8 مجم سوربيتول (نوع من السكر) لكل كبسولة رخوة. إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك الاتصال بطبيبك قبل أخذ هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ هذا الدواء دائمًا كما أخبرك طبيبك، وتحقق من طبيبك إن لم تكن متأكدًا.</p><p dir="RTL">الجرعة المعتادة هي 160 مجم (أربع كبسولات رخوة)، تؤخذ في نفس الوقت مرة واحدة يوميًا.</p><p dir="RTL"><strong>أخذ إنزاستيك</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ابتلع الكبسولات الرخوة كاملة مع بعض الماء.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تمضغ الكبسولات الرخوة أو تُذيبها أو تفتحها قبل الابتلاع.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يمكن أخذ إنزاستيك مع الطعام أو بدونه.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يجب عدم التعامل مع إنزاستيك من قبل أشخاص غير المريض ومقدمي الرعاية، وخاصة عدم التعامل من قبل النساء الحوامل أو المحتمل حملهن.</p><p dir="RTL">قد يصف الطبيب أيضًا أدوية أخرى أخذ إنزاستيك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أخذت أكثر مما يجب من إنزاستيك</strong></p><p dir="RTL">إن أخذت عددًا من الكبسولات أكثر مما يجب، توقف عن أخذ إنزاستيك وتواصل مع الطبيب. قد تُصبح أكثر عرضة للنوبات أو الآثار الجانبية الأخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول إنزاستيك</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن نسيت أخذ إنزاستيك في الموعد المعتاد، فخذ جرعتك المعتادة بمجرد تذكرك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن نسيت أخذ إنزاستيك ليوم كامل، فخذ جرعتك المعتادة في اليوم التالي.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا نسيت أخذ إنزاستيك لأكثر من يوم، تحدث مع طبيبك على الفور.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تتناول جرعة مزدوجة لتعويض الجرعة التي نسيتها.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن أخذ إنزاستيك</strong></p><p dir="RTL">لا تتوقف عن أخذ هذا الدواء مالم يطلب منك طبيبك فعل ذلك.</p><p>&nbsp;</p><p dir="RTL">تحدث مع طبيبك إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.</p><p dir="RTL"><strong>النوبات</strong></p><p dir="RTL">أُبلغ عن حدوث نوبات مع 4 لكل 1000 شخص يأخذ إنزاستيك، وأقل من واحد لكل 1000 شخص يأخذ الدواء الوهمي.</p><p dir="RTL">قد تزداد احتمالية حدوث النوبات إذا أخذت أكثر من الجرعة الموصي بها من هذا الدواء، أو أن أخذت أدوية محددة أخرى، أو إن كنت أكثر عرضة عن غيرك للإصابة بالنوبات.</p><p dir="RTL">يجب عليك استشارة طبيبك على وجه السرعة <strong>إن أُصبت بنوبة</strong>، فقد يقرر الطبيب ضرورة إيقاف إنزاستيك.</p><p>&nbsp;</p><p dir="RTL"><strong>متلازمة اعتلال الدماغ الخلفي العكسية (</strong><strong>PRES</strong><strong>)</strong></p><p dir="RTL">هناك تقارير نادرة عن حدوث متلازمة اعتلال الدماغ الخلفي العكسية (PRES) (قد تؤثر على 1 لكل 1000 شخص)، وهي حالة نادرة قابلة للشفاء تُصيب الدماغ، لدي المرضى الذين عولجوا بإنزاستيك. إن أُصبت بنوبة أو تفاقم بالصداع أو ارتباك أو عمى أو أي مشاكل بصرية أخرى، من فضلك تواصل مع طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشتمل الآثار الجانبية الأخرى على:</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تؤثر على أكثر من 1 لكل 10 أشخاص)</p><p dir="RTL">إرهاق، كسر العظام، دفق ساخن، ارتفاع ضغط الدم</p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على 1 لكل 10 أشخاص)</p><p dir="RTL">صداع، سقوط، شعور بالقلق، جفاف الجلد، حكة، صعوبة التذكر، انسداد شرايين القلب (داء القلب الإقفاري)، تضخم الثدي لدي الرجال (التثدي)، أعراض متلازمة تململ القدمين (حاجة غير مُتحكم فيها لتحريك جزء من الجسم، وعادة تكون القدمين)، انخفاض التركيز، نسيان</p><p dir="RTL"><strong>غير شائعة (</strong>قد تؤثر على 1 لكل 100 شخص)</p><p dir="RTL">هلاوس، صعوبة التفكير بوضوح، انخفاض أعداد خلايا الدم البيضاء</p><p dir="RTL"><strong>غير معلومة</strong> (لا يمكن تحديد التكرارية من البيانات المتاحة)</p><p dir="RTL">آلام العضلات، تشنجات العضلات، الضعف العضلي، ألم الظهر، تغيرات برسم القلب الكهربائي (ECG) (استطالة موجات QT)، اضطراب المعدة الذي يتضمن الشعور بالإعياء (غثيان)، طفح، إعياء (قيء)، تورم الوجه أو الشفتين أو اللسان أو الحلق أو كلاهم، انخفاض الصفائح الدموية (والذي يُزيد خطر التعرض للنزف أو الكدمات)، إسهال</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;إذا حدث لك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مدرجة بهذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.</p><p dir="RTL">&nbsp;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العبوة والزجاجة بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;يخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تستعمل أي كبسولة بها تسريب أو تالفة أو بها علامات دالة على التلاعب.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية، أسال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;مما يتكون إنزاستيك</strong></p><p dir="RTL">&nbsp;المادة الفعالة هي إينزالوتاميد.</p><p dir="RTL">&nbsp;تحتوي كل كبسولة على إينزالوتاميد 40 مجم.</p><p dir="RTL">&nbsp;المكونات الأخرى هي:</p><p dir="RTL"><em>&nbsp;المكونات الأخرى هي</em> بولي أوكسي جلسريدات الكابريلوكابريل، وبيوتيل هيدروكسي أنيسول، وبيوتيل هيدروكسي تولوين</p><p dir="RTL"><em>مكونات غلاف الكبسولة الرخوة</em> هي جيلاتين، محلول سوربيتول سوربيتان، جليسرين، ثاني أكسيد التيتانيوم.</p><p dir="RTL"><em>مكونات الحبر</em> هي أكسيد حديد أسود وهيبروميلوز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p><u>&nbsp;</u><u>إنزاستيك 40:</u></p><p>&nbsp;كبسولة جيلاتينية رخوة مستطيلة لونها أبيض إلى أبيض معتم، مطبوع عليها بالحبر الأسود &ldquo;E40&quot;، وتحتوي على محلول لونه أصفر فاتح إلى أصفر.</p><p dir="RTL">يحتوي كل كرتون على 112 كبسولة رخوة في 4 محافظ للشرائط بكل منها 28 كبسولة رخوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة :</strong></p><p dir="RTL">&nbsp;يوجيا فارما المتخصصة المحدودة،</p><p dir="RTL">مسح رقم 550 و551 و552، قرية كولثور،</p><p dir="RTL">منطقة شاميربيت، حي ميدشال-مالكاجيري،</p><p dir="RTL">&nbsp;تيلانجانا، الهند.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">أوروبيندو فارما المحدودة ،</p><p dir="RTL">قطعة رقم 2 ، ميتريفيهار ، أميربيت</p><p dir="RTL">حيدر أباد ، تيلانجانا ، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Enzastik 40 
(Enzalutamide Capsules 40 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enzalutamide Capsules 40 mg
Each capsule contains Enzalutamide 40 mg
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enzalutamide Capsules 40 mg
White to off-white oblong shape soft gelatin capsule imprinted in black ink with E40.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzalutamide is indicated for:</p><p>&bull; the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).</p><p>&bull; the treatment of adult men with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated</p><p>&bull; the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with enzalutamide should be initiated and supervised by specialist physicians experienced in the medical treatment of prostate cancer.</p><p><strong><em><u>Posology</u></em></strong></p><p>The recommended dose is 160 mg enzalutamide (four 40 mg soft capsules) as a single oral daily dose. Medical castration with a luteinising hormone-releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated.</p><p>If a patient misses taking enzalutamide at the usual time, the prescribed dose should be taken as close as possible to the usual time. If a patient misses a dose for a whole day, treatment should be resumed the following day with the usual daily dose.</p><p>If a patient experiences a &ge; Grade 3 toxicity or an intolerable adverse reaction, dosing should be withheld for one week or until symptoms improve to &le; Grade 2, then resumed at the same or a reduced dose (120 mg or 80 mg) if warranted.</p><p><strong><em><u>Concomitant use with strong CYP2C8 inhibitors</u></em></strong></p><p>The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily. If co-administration of the strong CYP2C8 inhibitor is discontinued, the enzalutamide dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor.</p><p><strong><em><u>Elderly</u></em></strong></p><p>No dose adjustment is necessary for elderly patients.</p><p><strong><em><u>Hepatic impairment</u></em></strong></p><p>No dose adjustment is necessary for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C, respectively). An increased half-life of enzalutamide may be observed in patients with severe hepatic impairment.</p><p><strong><em><u>Renal impairment</u></em></strong></p><p>No dose adjustment is necessary for patients with mild or moderate renal impairment. Caution is advised in patients with severe renal impairment or end-stage renal disease.</p><p><strong><em><u>Paediatric population</u></em></strong></p><p>There is no relevant use of enzalutamide in the paediatric population in the indication of treatment of adult men with CRPC.</p><p><strong><em><u>Method of administration</u></em></strong></p><p>Enzalutamide is for oral use. The soft capsules should not be chewed, dissolved or opened but should be swallowed whole with water, and can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients 
Women who are or may become pregnant.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Risk of seizure</u></strong></p><p>Use of enzalutamide has been associated with seizure. The decision to continue treatment in patients who develop seizure should be taken case by case.</p><p><strong><u>Posterior reversible encephalopathy syndrome</u></strong></p><p>There have been rare reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving Enzalutamide. PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinuation of Enzalutamide in patients who develop PRES is recommended.</p><p><strong><u>Concomitant use with other medicinal products</u></strong></p><p>Enzalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products. A review of concomitant medicinal products should therefore be conducted when initiating enzalutamide treatment. Concomitant use of enzalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations.</p><p>Co-administration with warfarin and coumarin-like anticoagulants should be avoided. If Enzalutamide is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted.</p><p><strong><u>Renal impairment</u></strong></p><p>Caution is required in patients with severe renal impairment as enzalutamide has not been studied in this patient population.</p><p><strong><u>Severe hepatic impairment</u></strong></p><p>An increased half-life of enzalutamide may be observed in patients with severe hepatic impairment, possibly related to increased tissue distribution. The clinical relevance of this observation remains unknown. A prolonged time to reach steady state concentrations is however anticipated, and the time to maximum pharmacological effect as well as time for onset and decline of enzyme induction may be increased.</p><p><strong><u>Recent cardiovascular disease</u></strong></p><p>Caution is required in patients with recent myocardial infarction (in the past 6 months) or unstable angina (in the past 3 months) as enzalutamide has not been studied in this patient population.</p><p><strong><u>Androgen deprivation therapy may prolong the QT interval </u></strong></p><p>In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval physicians should assess the benefit risk ratio including the potential for Torsade de pointes prior to initiating Enzalutamide.</p><p><strong><u>Use with chemotherapy</u></strong></p><p>The safety and efficacy of concomitant use of Enzalutamide with cytotoxic chemotherapy has not been established. Coadministration of enzalutamide has no clinically relevant effect on the pharmacokinetics of intravenous docetaxel; however, an increase in the occurrence of docetaxel-induced neutropenia cannot be excluded.</p><p><strong><u>Excipients</u></strong></p><p>Enzalutamide contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.</p><p><strong><u>Hypersensitivity reactions</u></strong></p><p>Hypersensitivity reactions manifested by symptoms including, but not limited to, rash, or face, tongue, lip, or pharyngeal oedema, have been observed with enzalutamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Potential for other medicinal products to affect enzalutamide exposures</u></strong></p><p><em>CYP2C8 inhibitors</em></p><p>CYP2C8 plays an important role in the elimination of enzalutamide and in the formation of its active metabolite. Strong inhibitors (e.g. gemfibrozil) of CYP2C8 are to be avoided or used with caution during enzalutamide treatment. If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily.</p><p><em>CYP3A4 inhibitors</em></p><p>CYP3A4 plays a minor role in the metabolism of enzalutamide. No dose adjustment is necessary when Enzalutamide is co-administered with inhibitors of CYP3A4.</p><p><em>CYP2C8 and CYP3A4 inducers</em></p><p>No dose adjustment is necessary when Enzalutamide is co-administered with inducers of CYP2C8 or CYP3A4.</p><p><strong><u>Potential for enzalutamide to affect exposures to other medicinal products</u></strong></p><p><em>Enzyme induction</em></p><p>Enzalutamide is a potent enzyme inducer and increases the synthesis of many enzymes and transporters; therefore, interaction with many common medicinal products that are substrates of enzymes or transporters is expected. The reduction in plasma concentrations can be substantial, and lead to lost or reduced clinical effect. There is also a risk of increased formation of active metabolites. Enzymes that may be induced include CYP3A in the liver and gut, CYP2B6, CYP2C9, CYP2C19, and uridine 5&#39;-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enzymes). The transport protein P-gp may also be induced, and probably other transporters as well, e.g. multidrug resistance associated protein 2 (MRP2), breast cancer resistance protein (BCRP) and the organic anion transporting polypeptide 1B1 (OATP1B1).</p><p>Interactions with certain medicinal products that are eliminated through metabolism or active transport are expected. If their therapeutic effect is of large importance to the patient, and dose adjustments are not easily performed based on monitoring of efficacy or plasma concentrations, these medicinal products are to be avoided or used with caution. The risk for liver injury after paracetamol administration is suspected to be higher in patients concomitantly treated with enzyme inducers.</p><p>Groups of medicinal products that can be affected include, but are not limited to:</p><p>&bull; Analgesics (e.g. fentanyl, tramadol)</p><p>&bull; Antibiotics (e.g. clarithromycin, doxycycline)</p><p>&bull; Anticancer agents (e.g. cabazitaxel)</p><p>&bull; Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)</p><p>&bull; Antipsychotics (e.g. haloperidol)</p><p>&bull; Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)</p><p>&bull; Betablockers (e.g. bisoprolol, propranolol)</p><p>&bull; Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)</p><p>&bull; Cardiac glycosides (e.g. digoxin)</p><p>&bull; Corticosteroids (e.g. dexamethasone, prednisolone)</p><p>&bull; HIV antivirals (e.g. indinavir, ritonavir)</p><p>&bull; Hypnotics (e.g. diazepam, midazolam, zolpidem)</p><p>&bull; Immunosuppressant (e.g. tacrolimus)</p><p>&bull; Proton pump inhibitor (e.g. omeprazole)</p><p>&bull; Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)</p><p>&bull; Thyroid agents (e.g. levothyroxine)</p><p>The full induction potential of enzalutamide may not occur until approximately 1 month after the start of treatment, when steady-state plasma concentrations of enzalutamide are reached, although some induction effects may be apparent earlier. Patients taking medicinal products that are substrates of CYP2B6, CYP3A4, CYP2C9, CYP2C19 or UGT1A1 should be evaluated for possible loss of pharmacological effects (or increase in effects in cases where active metabolites are formed) during the first month of enzalutamide treatment and dose adjustment should be considered as appropriate.</p><p>In consideration of the long half-life of enzalutamide (5.8 days), effects on enzymes may persist for one month or longer after stopping enzalutamide. A gradual dose reduction of the concomitant medicinal product may be necessary when stopping enzalutamide treatment.</p><p><em>CYP1A2 and CYP2C8 substrates </em></p><p>No dose adjustment is indicated when a CYP1A2 or CYP2C8 substrate is co-administered with Enzalutamide.</p><p><em>P-gp substrates</em></p><p>Medicinal products with a narrow therapeutic range that are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used with caution when administered concomitantly with Enzalutamide and may require dose adjustment to maintain optimal plasma concentrations.</p><p><em>BCRP, MRP2, OAT3 and OCT1 substrates</em></p><p>Inhibition of BCRP and MRP2 (in the intestine), as well as organic anion transporter 3 (OAT3) and organic cation transporter 1 (OCT1) (systemically) cannot be excluded. Theoretically, induction of these transporters is also possible, and the net effect is presently unknown.</p><p><em>Medicinal products which prolong the QT interval</em></p><p>Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Enzalutamide with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated.</p><p><strong><u>Effect of food on enzalutamide exposures</u></strong></p><p>Food has no clinically significant effect on the extent of exposure to enzalutamide. Enzalutamide may be administered without regard to food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Women of childbearing potential</u></strong></p><p>This medicine may cause harm to the unborn child or potential loss of pregnancy if taken by women who are pregnant.</p><p><strong><u>Contraception in males and females</u></strong></p><p>It is not known whether enzalutamide or its metabolites are present in semen. A condom is required during and for 3 months after treatment with enzalutamide if the patient is engaged in sexual activity with a pregnant woman. If the patient engages in sexual intercourse with a woman of childbearing potential, a condom and another form of birth control must be used during and for 3 months after treatment. Studies in animals have shown reproductive toxicity.</p><p><strong><u>Pregnancy</u></strong></p><p>Enzalutamide is not for use in women. Enzalutamide is contraindicated in women who are or may become pregnant.</p><p><strong><u>Breast-feeding</u></strong></p><p>Enzalutamide is not for use in women. It is not known if enzalutamide is present in human milk. Enzalutamide and/or its metabolites are secreted in rat milk.</p><p><strong><u>Fertility</u></strong></p><p>Animal studies showed that enzalutamide affected the reproductive system in male rats and dogs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzalutamide has moderate influence on the ability to drive and use machines as psychiatric and neurologic events including seizure may be reported.</p><p>Patients should be advised of the potential risk of experiencing a psychiatric or neurological event while driving or operating machines.</p><p>No studies to establish the effects of enzalutamide on the ability to drive and use machines have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are asthenia/fatigue, hot flush, fractures, and hypertension. Other important adverse reactions include fall, cognitive disorder, and neutropenia.</p><p>Adverse reactions are listed below by frequency category. Frequency categories are defined as follows:</p><p>very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Table: Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p>MedDRA System organ class</p></td><td style="vertical-align:top"><p>Adverse reaction and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p><p>disorders</p></td><td style="vertical-align:top"><p>Uncommon: leucopenia, neutropenia</p><p>not known*: thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Not known*: &nbsp;face oedema, tongue oedema, lip oedema, pharyngeal oedema</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common: anxiety</p><p>uncommon: visual hallucinations</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>common: headache, memory impairment, amnesia, disturbance in attention, restless legs</p><p>syndrome</p><p>uncommon: cognitive disorder, seizure</p><p>not known*: posterior reversible encephalopathy syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common: ischemic heart disease</p><p>Not known*: QT-prolongation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very common: hot flush, hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Not known*: nausea, vomiting, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>Common: dry skin, pruritus</p><p>not known*: rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective</p><p>tissue disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Common: fractures**</p><p>not known*: myalgia, muscle spasms, muscular weakness, back pain</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast</p><p>disorder</p></td><td style="vertical-align:top"><p>Common: gynaecomastia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration</p><p>site conditions</p></td><td style="vertical-align:top"><p>Very common: asthenia/fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural</p><p>complications</p></td><td style="vertical-align:top"><p>Common: fall</p></td></tr></tbody></table><p>* Spontaneous reports from post-marketing experience</p><p>** Includes all fractures with the exception of pathological fractures</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><ul><li>Saudi Arabia:</li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - The National Pharmacovigilance Center (NPC):</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340.</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no antidote for enzalutamide. In the event of an overdose, treatment with enzalutamide should be stopped and general supportive measures initiated taking into consideration the half-life of 5.8 days.</p><p>Patients may be at increased risk of seizures following an overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong></p><p>hormone antagonists and related agents, anti-androgens, ATC code: L02BB04.</p><p><strong><u>Mechanism of action</u></strong></p><p>Prostate cancer is known to be androgen sensitive and responds to inhibition of androgen receptor signalling. Despite low or even undetectable levels of serum androgen, androgen receptor signalling continues to promote disease progression. Stimulation of tumour cell growth via the androgen receptor requires nuclear localization and DNA binding.</p><p>Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens. Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression. In preclinical studies enzalutamide lacks androgen receptor agonist activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzalutamide is poorly water soluble. The solubility of enzalutamide is increased by caprylocaproyl macrogolglycerides as emulsifier/surfactant.</p><p>The mean terminal half-life (t1/2) for enzalutamide is 5.8 days (range 2.8 to 10.2 days), and steady state will be achieved in approximately one month. With daily oral administration, enzalutamide accumulates approximately 8.3-fold relative to a single dose. Daily fluctuations in plasma concentrations are low (peak-to-trough ratio of 1.25). Clearance of enzalutamide is primarily via hepatic metabolism, producing an active metabolite that is equally as active as enzalutamide and circulates at approximately the same plasma concentration as enzalutamide.</p><p><strong><u>Absorption</u></strong></p><p>Maximum plasma concentrations (Cmax) of enzalutamide in patients may be observed 1 to 2 hours after administration. Oral absorption of enzalutamide is estimated to be at least 84.2%. Enzalutamide is not a substrate of the efflux transporters P-gp or BCRP. At steady state, the mean Cmax values for enzalutamide and its active metabolite are 16.6 &mu;g/mL (23% coefficient of variation [CV]) and 12.7 &mu;g/mL (30% CV), respectively.</p><p>Food has no clinically significant effect on the extent of absorption. Enzalutamide may be administered without regard to food.</p><p><strong><u>Distribution</u></strong></p><p>The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L (29% CV).</p><p>The volume of distribution of enzalutamide is greater than the volume of total body water, indicative of extensive extravascular distribution. Studies in rodents indicate that enzalutamide and its active metabolite can cross the blood brain barrier.</p><p>Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. The active metabolite is 95% bound to plasma proteins. There was no protein binding displacement between enzalutamide and other highly bound medicinal products (warfarin, ibuprofen and salicylic acid) <em>in vitro</em>.</p><p><strong><u>Biotransformation</u></strong></p><p>Enzalutamide is extensively metabolised. There are two major metabolites in human plasma: N-desmethyl enzalutamide (active) and a carboxylic acid derivative (inactive). Enzalutamide is metabolised by CYP2C8 and to a lesser extent by CYP3A4/5, both of which play a role in the formation of the active metabolite. <em>In vitro</em>, N-desmethyl enzalutamide is metabolised to the carboxylic acid metabolite by carboxylesterase 1, which also plays a minor role in the metabolism of enzalutamide to the carboxylic acid metabolite. N-desmethyl enzalutamide was not metabolised by CYPs <em>in vitro</em>.</p><p>Enzalutamide is a strong inducer of CYP3A4, a moderate inducer of CYP2C9 and CYP2C19, and has no clinically relevant effect on CYP2C8.</p><p><strong><u>Elimination</u></strong></p><p>The mean apparent clearance (CL/F) of enzalutamide in patients ranges from 0.520 and 0.564 L/h.</p><p>Following oral administration of 14C-enzalutamide, 84.6% will be recovered by 77 days post dose: 71.0% is recovered in urine (primarily as the inactive metabolite, with trace amounts of enzalutamide and the active metabolite), and 13.6% is recovered in faeces (0.39% of dose as unchanged enzalutamide).</p><p><strong><u>Linearity</u></strong></p><p>No major deviations from dose proportionality may be observed over the dose range 40 to 160 mg.</p><p><strong><u>Renal impairment</u></strong></p><p>No dose adjustment is necessary for patients with calculated creatinine clearance (CrCL) values &ge; 30 mL/min (estimated by the Cockcroft and Gault formula). Caution is advised when treating these patients with severe renal impairment (CrCL &lt; 30 mL/min) or end-stage renal disease. It is unlikely that enzalutamide will be significantly removed by intermittent haemodialysis or continuous ambulatory peritoneal dialysis.</p><p><strong><u>Hepatic impairment</u></strong></p><p>Hepatic impairment did not have a pronounced effect on the total exposure to enzalutamide or its active metabolite. The half-life of enzalutamide was however doubled in patients with severe hepatic impairment compared with healthy controls (10.4 days compared to 4.7 days), possibly related to an increased tissue distribution.</p><p><strong><u>Elderly </u></strong></p><p>No clinically relevant effect of age on enzalutamide pharmacokinetics was seen in the elderly population pharmacokinetic analysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enzalutamide treatment of pregnant mice resulted in an increased incidence of embryo-fetal deaths and external and skeletal changes. Reproductive toxicology studies were not conducted with Enzalutamide, but in studies in rats (4 and 26 weeks) and dogs (4, 13, and 39 weeks), atrophy, aspermia/hypospermia, and hypertrophy/hyperplasia in the reproductive system were noted, consistent with the pharmacological activity of Enzalutamide. In studies in mice (4 weeks), rats (4 and 26 weeks) and dogs (4, 13, and 39 weeks), changes in the reproductive organs associated with Enzalutamide were decreases in organ weight with atrophy of the prostate and epididymis. Leydig cell hypertrophy and/or hyperplasia were observed in mice (4 weeks) and dogs (39 weeks). Additional changes to reproductive tissues included hypertrophy/hyperplasia of the pituitary gland and atrophy in seminal vesicles in rats and testicular hypospermia and seminiferous tubule degeneration in dogs. Gender differences were noted in rat mammary glands (male atrophy and female lobular hyperplasia). Changes in the reproductive organs in both species were consistent with the pharmacological activity of Enzalutamide and reversed or partially resolved after an 8-week recovery period. There were no other important changes in clinical pathology or histopathology in any other organ system, including the liver, in either species.</p><p>Studies in pregnant rats have shown that Enzalutamide and/or its metabolites are transferred to fetuses. After oral administration of radiolabeled 14C-enzalutamide to rats on day 14 of pregnancy at a dose of 30 mg/kg (~ 1.9 times the maximum dose indicated in humans), the maximum radioactivity in the fetus was reached 4 hours after administration and was lower than that in the maternal plasma with tissue/plasma ratio of 0.27. The radioactivity in the fetus decreased to 0.08 times the maximum concentration at 72 hours after administration.</p><p>Studies in lactating rats have shown that Enzalutamide and/or its metabolites are secreted in rat milk. After oral administration of radiolabeled 14C-enzalutamide to lactating rats at a dose of 30 mg/kg (~ 1.9 times the maximum dose indicated in humans), the maximum radioactivity in the milk was reached 4 hours after administration and was up to 3.54-fold higher than that in the maternal plasma. Study results also have shown that Enzalutamide and/or its metabolites are transferred to infant rat tissues via milk and subsequently eliminated.</p><p>Enzalutamide was negative for genotoxicity in a standard battery of <em>in vitro </em>and <em>in vivo </em>tests. In a 6-month study in transgenic rasH2 mice, Enzalutamide did not show carcinogenic potential (absence of neoplastic findings) at doses up to 20 mg/kg per day (AUC24h ~317 &micro;g.h/mL), which resulted in plasma exposure levels similar to the clinical exposure (AUC24h 322 &micro;g&bull;h/mL) in mCRPC patients receiving 160 mg, daily.</p><p>Daily dosing of rats for two years with enzalutamide at 10&ndash;100 mg/kg/day produced an increased incidence of several, mostly benign, tumour types. The most prominent of these were benign Leydig cell tumours, urothelium papilloma, and carcinoma of urinary bladder. Benign Leydig cell tumours are expected based on the pharmacological properties of this antiandrogen drug and not considered relevant to humans. Some urothelium papilloma and carcinoma of urinary bladder is expected in rats based on the horizontal structure of the rat urinary bladder, which can encounter concentrated urine and prolonged irritation from calculi. In the study, calculi and crystals were observed in rat urinary bladders. However, no obvious mechanistic rationale to explain specifically this malignancy can be established, and taking into account that exposure levels, based on AUC, achieved in the study, for enzalutamide plus its metabolites, were less than or similar to those in prostate cancer patients at the recommended dose of 160 mg/day, urinary bladder carcinogenicity potential of Enzalutamide in humans cannot be excluded. Other tumours, which are also potentially related to the primary pharmacology include fibroadenoma of mammary glands and benign thymoma of thymus in males, benign granulosa cell tumours of ovaries in females, and adenoma of pituitary pars distalis in both sexes. The exposure levels achieved in this study in male rats at Week 26 at 100 mg/kg per day for enzalutamide plus its active metabolites M1 and M2 (AUC24: Enzalutamide ~457 &micro;g&bull;h/mL, M1 ~321 &micro;g&bull;h/mL, M2 ~35 &micro;g&bull;h/mL) were less than or similar to those in prostate cancer patients at the recommended dose (160 mg/day) of enzalutamide (AUC24: Enzalutamide ~322 &micro;g&bull;h/mL, M1 ~193 &micro;g&bull;h/mL, M2 ~278 &micro;g&bull;h/mL).</p><p>Enzalutamide was not phototoxic <em>in vitro</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caprylocaproyl polyoxyglerides, Butylhydroxyanisole, Butylhydroxytoluene, Gelatin, Sorbitol Sorbitan Solution, Glycerin, Titanium Dioxide, Purified water, Opacode WB Black NS-78-17821, Triglycerides Medium-chain, KIMTECH pure W4 wipers, Isopropyl alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Keep out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton contains 112 soft capsules in 4 blister wallets of 28 soft capsules each.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
Eugia Pharma Specialities Limited,
Sy No. 550, 551 & 552, Kolthur (Village), Shamirpet (Mandal),
Medchal-Malkajgiri District, Telangana, India.

Marketing Authorization Holder:
Aurobindo Pharma Limited,
Plot No.: 2, Maitrivihar,
Ameerpet, Hyderabad-500 038,
Telangana, India.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>